SCHEMBL5143034

SCHEMBL5143034

Cc1ccc(C(=O)O)cc1-c1ccc(C=C2NC(=O)NC2=O)o1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 8/20 0.65
MAPT P10636 7/20 0.65
MEN1 O00255 7/20 0.65
KMT2A Q03164 7/20 0.65
TDP1 Q9NUW8 7/20 0.65
KDM4E B2RXH2 6/20 0.65
CTDSP1 Q9GZU7 6/20 0.65
ALDH1A1 P00352 6/20 0.65
APEX1 P27695 5/20 0.65
RECQL P46063 4/20 0.65
HPGD P15428 2/20 0.65
DNMT1 P26358 2/20 0.65
PSMD14 O00487 1/20 0.65
MMP2 P08253 1/20 0.65
L3MBTL1 Q9Y468 6/20 0.62
MCL1 Q07820 2/20 0.53
LMNA P02545 1/20 0.53
GSK3A P49840 4/20 0.53
GSK3B P49841 4/20 0.53
PPM1G O15355 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5143032 1.00 POLB (0.65) POLBMAPTMEN1KMT2ATDP1
SCHEMBL5143410 0.91 PPM1G (0.62) POLBMAPTMEN1KMT2ATDP1
SCHEMBL5143408 0.91 PPM1G (0.62) POLBMAPTMEN1KMT2ATDP1
SCHEMBL12990390 0.81 GSK3A (0.77) POLBMAPTMEN1KMT2ATDP1
SCHEMBL3362481 0.81 GSK3A (0.77) POLBMAPTMEN1KMT2ATDP1
SCHEMBL3362480 0.81 GSK3A (0.77) POLBMAPTMEN1KMT2ATDP1
SCHEMBL30657757 0.79 INSR (0.69) POLBMAPTMEN1KMT2ATDP1
SCHEMBL3365349 0.79 GSK3A (0.79) POLBMAPTMEN1KMT2ATDP1
SCHEMBL12990771 0.79 GSK3A (0.79) POLBMAPTMEN1KMT2ATDP1
SCHEMBL3365346 0.79 GSK3A (0.79) POLBMAPTMEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1718308-A4 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORP (CA) 2007-07-18 EP disclosed
EP-1718308-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PainCeptor Pharma Corp. (CA) 2006-11-08 EP disclosed
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity PAINCEPTOR PHARMA CORPORATION (CA) 2005-12-22 US disclosed
WO-2005076695-A2 METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY PAINCEPTOR PHARMA CORPORATION (CA) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282840-A1 Methods of modulating neurotrophin-mediated activity NGF, BDNF, NTRK2 POLB 2945/4885MAPT 2096/4885MEN1 4004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.